Ginkgo Bioworks to go public in a $15B SPAC deal
The deal values the company at $15 billion or 24.1x 2024E revenues. The deal is expected to close in the third quarter of 2021. Ginkgo Bioworks, a biotech company based in Boston, announced that it will go public via a merger with Soaring Eagle Acquisition Corp. (SRNG), a special purpose acquisition vehicle (SPAC), in a deal that gives the company a pre-money equity valuation of $15 billion. The company expects to receive proceeds of $2.5 billion as part of the deal. Shares of Soaring Eagle Acq...
Source: invezz.com